# Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

> **NCT00281658** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 444 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib (GW572016) oral tablets
- **DRUG:** Paclitaxel infusion
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00281658
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-02
- **Primary completion:** 2010-06-18
- **Final completion:** 2021-11-23
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281658, "Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00281658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*